REBORNE
Regenerating Bone defects using New biomedical Engineering approaches
| Coordinatore | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
Organization address
address: 101 Rue de Tolbiac contact info |
| Nazionalità Coordinatore | France [FR] |
| Totale costo | 15˙472˙075 € |
| EC contributo | 11˙935˙340 € |
| Programma | FP7-HEALTH
Specific Programme "Cooperation": Health |
| Code Call | FP7-HEALTH-2009-single-stage |
| Funding Scheme | CP-IP |
| Anno di inizio | 2010 |
| Periodo (anno-mese-giorno) | 2010-01-01 - 2015-06-30 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
Organization address
address: 101 Rue de Tolbiac contact info |
FR (PARIS) | coordinator | 2˙121˙051.00 |
| 2 |
ETABLISSEMENT FRANCAIS DU SANG
Organization address
address: AVENUE DU STADE DE FRANCE 20 contact info |
FR (LA PLAINE SAINT DENIS CEDEX) | participant | 1˙439˙351.40 |
| 3 |
UNIVERSITAET ULM
Organization address
address: HELMHOLTZSTRASSE 16 contact info |
DE (ULM) | participant | 1˙356˙006.40 |
| 4 |
UNIVERSITA DEGLI STUDI DI MODENA E REGGIO EMILIA
Organization address
address: VIA UNIVERSITA 4 contact info |
IT (MODENA) | participant | 803˙109.25 |
| 5 |
UNIVERSIDAD AUTONOMA DE MADRID
Organization address
address: CALLE EINSTEIN, CIUDAD UNIV CANTOBLANCO RECTORADO 3 contact info |
ES (MADRID) | participant | 630˙499.50 |
| 6 |
FONDAZIONE IRCCS CA' GRANDA - OSPEDALE MAGGIORE POLICLINICO
Organization address
address: VIA FRANCESCO SFORZA 28 contact info |
IT (MILANO) | participant | 546˙715.56 |
| 7 |
UNIVERSITA DEGLI STUDI DI VERONA
Organization address
address: VIA DELL ARTIGLIERE 8 contact info |
IT (VERONA) | participant | 481˙199.62 |
| 8 |
BIOMATLANTE SAS
Organization address
address: rue Edouard Belin - ZA des IV Nations 5 contact info |
FR (VIGNEUX DE BRETAGNE) | participant | 477˙500.00 |
| 9 |
EBERHARD KARLS UNIVERSITAET TUEBINGEN
Organization address
address: GESCHWISTER-SCHOLL-PLATZ contact info |
DE (TUEBINGEN) | participant | 465˙696.00 |
| 10 |
UNIVERSITETET I BERGEN
Organization address
address: Museplassen 1 contact info |
NO (BERGEN) | participant | 409˙868.75 |
| 11 |
XPAND BIOTECHNOLOGY BV
Organization address
address: PROFESSOR BRONKHORSTLAAN 10D contact info |
NL (BILTHOVEN) | participant | 401˙600.00 |
| 12 |
ALCIMED
Organization address
address: BOULEVARD DE MONTMORENCY 57 contact info |
FR (PARIS) | participant | 374˙964.00 |
| 13 |
ISTITUTO ORTOPEDICO RIZZOLI
Organization address
address: VIA DI BARBIANO 1/10 contact info |
IT (BOLOGNA) | participant | 363˙180.00 |
| 14 |
MAX PLANCK GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V.
Organization address
address: Hofgartenstrasse 8 contact info |
DE (MUENCHEN) | participant | 352˙448.88 |
| 15 |
UNIVERSITAT POLITECNICA DE CATALUNYA
Organization address
address: Jordi Girona 31 contact info |
ES (BARCELONA) | participant | 304˙855.00 |
| 16 |
KITOZYME SA
Organization address
address: RUE HAUTE CLAIRE PARC INDUSTRIEL 4 contact info |
BE (HERSTAL) | participant | 300˙160.00 |
| 17 |
UNIVERSITATEA DE MEDICINA SI FARMACE VICTOR BABES TIMISOARA
Organization address
address: PIATA EFTIMIE MURGU 2A contact info |
RO (TIMISOARA) | participant | 247˙600.00 |
| 18 |
COMMISSARIAT A L ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES
Organization address
address: RUE LEBLANC 25 contact info |
FR (PARIS 15) | participant | 224˙994.00 |
| 19 |
UNIVERSITAIR MEDISCH CENTRUM UTRECHT
Organization address
address: HEIDELBERGLAAN 100 contact info |
NL (UTRECHT) | participant | 199˙940.00 |
| 20 |
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS
Organization address
address: 3 Avenue Victoria contact info |
FR (PARIS) | participant | 121˙388.00 |
| 21 |
HOPITAL UNIVERSTAIRE DE TOURS
Organization address
city: TOURS CEDEX 1 contact info |
FR (TOURS CEDEX 1) | participant | 112˙050.00 |
| 22 |
CENTRE HOSPITALIER UNIVERSITAIRE DE NANTES
Organization address
address: Allee de l'Ile Gloriette 5 contact info |
FR (NANTES) | participant | 99˙892.17 |
| 23 |
AZIENDA OSPEDALIERO-UNIVERSITARIA ANNA MEYER
Organization address
address: VIALE PIERACCINI 24 contact info |
IT (FIRENZE) | participant | 88˙800.00 |
| 24 |
UNIVERSITE DE LIEGE
Organization address
city: LIEGE contact info |
BE (LIEGE) | participant | 12˙470.40 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'Bone is among the most frequently transplanted tissue with about 1 million procedures annually in Europe. The worldwide market of bone replacement materials is currently estimated at 5 billion € with a 10% annual growth. Despite their considerable disadvantages, including the risk of disease transfer and immunologic rejection, limited supply of bone, costs and complications, allografts and autografts account for more than 80% of total graft volume. Significant growth opportunities exist for synthetic bone grafts in association with mesenchymal stem cells from autologous or allogenic sources as alternatives to biological bone grafts in orthopaedic and maxillofacial surgery. The objectives of REBORNE is to perform clinical trials using advanced biomaterials and cells triggering bone healing in patients. In order to reach this goal, five phase II clinical studies with 20 patients are proposed in 12 clinical centres spread in 8 European countries. Three orthopaedic trials concerning the treatment of long bone fractures and osteonecrosis of the femoral head in adults or children will be conducted using bioceramics, hydrogel for percuteneous injection and stem cells from autologous or allogenic sources. Clinical research will also concern maxillofacial surgery with bone augmentation prior to dental implants and the reconstruction of cleft palates in children. The safety and efficacy of the new therapies will be assessed clinically using X-rays, CT scans and MRI as well as histology of biopsies. These ambitious clinical targets will require research and development efforts from a large consortium of top world class laboratories, SMEs manufacturing biomaterials, GMP-cell producing facilities and surgeons in hospitals as well as the consideration of ethical and regulatory issues. It is expected that REBORNE will expand the competitiveness of Europe through the patenting of new CE-marked bioproducts in the field of regenerative medicine.'
Introduzione (Teaser)
Bone tissue engineering is a novel approach that has received much attention lately as a promising alternative to autologous bone transplantation. An EU-funded study proposed the utilisation of mesenchymal stem cells (MSCs) for bone regeneration.